NIO Inc. vs Viatris Inc — how do they compare? NIO Inc. trades at $3.67 (market cap $9.23B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 2.1× NIO Inc.'s market cap, and Viatris Inc pays a 2.89% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | VTRS | |
|---|---|---|
Market Cap | $9.23B | $19.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $17.86 |
52-Week Low | $3.70 | $9.49 |
Enterprise Value | $7.13B | $31.21B |
Dividend Yield | — | 2.89% |
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.79, down 0.26% over 24 hours, with a bearish technical signal but improving fundamentals. Recent Q2 2026 earnings beat expectations with a narrower loss, while revenue grew 69.1% year-over-year to $4.74 billion (Seeking Alpha, 2026-09-03). The stock faces headwinds from a weak Chinese EV market but shows progress toward profitability with positive operating cash flow in Q2.
The outlook is mixed: analyst consensus is bullish with a $5.50 price target (50% buy ratings), but risks include high debt, competition, and macroeconomic pressures. Upside depends on sustained delivery growth and margin expansion, while downside risks loom from cost inflation and market sentiment shifts.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Trailing returns across standard periods
Latest headlines on both assets
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →